Clinical trial of Peiyuan Tongnao capsules in the treatment of patients in the recovery period of ischemic stroke
10.13699/j.cnki.1001-6821.2024.04.002
- VernacularTitle:培元通脑胶囊在缺血性脑卒中恢复期患者的临床研究
- Author:
Meng-Di WANG
1
;
Ying-Bo ZHAO
;
Yue SUN
;
Di ZHANG
Author Information
1. 黑龙江中医药大学研究生院,黑龙江哈尔滨 150006
- Keywords:
Peiyuan Tongnao capsule;
schemic stroke;
clinical efficacy;
nerve function;
traditional Chinese medicine syndrome score
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(4):487-491
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the improvement value of Peiyuan Tongnao capsule on nerve function in patients.Methods Retrospective cohort analysis of patients with ischemic stroke was performed.Control group was treated for 12 weeks by oral aspirin enteric-coated tablets(100 mg,qd each time),intravenous infusion of low molecular dextran 500 mL(qd),oral atorvastatin calcium 20 mg(qd);the treatment group was treated with Peiyuan Tongnao capsule 1.8 g(tid)for 12 weeks on the basis of the control group.After 12 weeks of treatment,clinical efficacy,neurological function[National Institutes of Health Neurological impairment(NIHSS)score],traditional Chinese medicine(TCM)syndrome score,laboratory indexes[calcitonin gene-related peptide(CGRP),plasma D-dimer(D-D),neutrophil to lymphocyte ratio(NLR)],and hemorheological indexes[whole blood viscosity,platelets aggregation rate,fibrinogen(FIB),blood sedimentation rate(ESR)]were compared between the two groups,and incidence of adverse drug reactions during treatment.Results After 12 weeks of treatment,the total effective rate of treatment group and control group was 77.50％(31 cases/40 cases)and 55.00％(22 cases/40 cases),respectively,and the difference was statistically significant(P＜0.05).After 12 weeks of treatment,the NIHSS scores of treatment group and control group were(6.09±1.03)and(10.23±2.03)points;the TCM syndrome scores were(12.57±2.82)and(15.78±3.12)points;CGRP levels were(35.47±6.24)and(30.12±6.11)pg·mL-1;D-D levels were(0.31±0.09)and(0.56±0.11)mg·mL-1;NLR levels were 4.76±1.23 and 3.06±0.91;whole blood viscosity were(3.11±0.62)and(3.74±0.84)mPa·s-1;platelet aggregation rate were(48.21±5.11)％and(54.69±6.31)％;FIB level were(2.41±0.32)and(3.11±0.49)g·L-1;ESR were(18.11±2.06)and(23.45±2.15)mm·h-1,respectively.The above indexes in treatment group were significantly different from those in control group(all P＜0.05).There were 6 cases of adverse drug reactions in the treatment group,and the incidence of adverse drug reactions was 15.00％,while 8 cases in the control group,and the total incidence of adverse drug reactions was 20.00％,the difference was not statistically significant(P＞0.05).Conclusion Conventional treatment combined with Peiyuan Tongnao capsule has better efficacy than conventional treatment for ischemic stroke,which can improve nerve function and hemorheology and improve clinical efficacy.
